Abstract
Vigabatrin (VGB) is an effective add-on anti-epileptic drug. The major serious adverse drug reactions (ADRs) are behavioural and psychiatric disturbances. This study does not support the view that a previous history of behavioural and psychiatric features increases the risk of behavioural/psychiatric ADRs (relative risk 1.23, 95% CI 0.57-2.66, P = 0.61). The results suggest that a low starting does of vigabatrin does not reduce the risk of psychiatric and behavioural ADRs (P = 0.31) or prevent a more overt psychotic reaction from occurring.
Publication types
-
Clinical Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Adult
-
Aged
-
Anticonvulsants / adverse effects*
-
Anticonvulsants / therapeutic use*
-
Child
-
Epilepsy / drug therapy*
-
Female
-
Follow-Up Studies
-
Humans
-
Male
-
Mental Disorders / chemically induced
-
Mental Disorders / epidemiology*
-
Middle Aged
-
Retrospective Studies
-
Vigabatrin
-
gamma-Aminobutyric Acid / adverse effects
-
gamma-Aminobutyric Acid / analogs & derivatives*
-
gamma-Aminobutyric Acid / therapeutic use
Substances
-
Anticonvulsants
-
gamma-Aminobutyric Acid
-
Vigabatrin